View Author
Schaefer, U.W.
( U.W. Schaefer)
patient ebv reactivation reactivation ebv-lpd transplantation epstein-barr disease blood graft virus lymphoproliferative number donor epstein-barr virus marrow transplant analysis tcd-sct recipient allo-sct table j clin microbiol cell transplantation risk factors posttransplant lymphoproliferative disease value disorder plasma factor unmanipulated allogeneic conditioning regimen incidence bone marrow transplantation 1.35 106/ kg level therapy bone marrow transplant range ebv-dna study cd 34 cells unmanipulated allo-sct 1000 geq /ml epstein-barr virus dna diagnosis geq /ml non-tcd tcd graft figure multivariate analysis antibody bone marrow donor graft lymphocytes cytokine regimen count polymerase chain reaction posttransplant plasma ebv-dna level group conditioning 50 geq /ml b-cell br j haematol unmanipulated sct leukemia myeloid leukemia lymphoproliferative disorders non-tcd group antithymocyte globulin multivariate depletion donor sct nontcd-sct detection microbiol lymphoproliferative disease day 180
1 Most Recent Publications
|
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV- lymphoproliferative disease following T-cell--depleted SCT
(Article)
Esser, J.W.J. van Holt, B. van der Bacigalupo, A. Löwenberg, B. Schaefer, U.W. Gratama, J-W. Osterhaus, A.D.M.E. Meijer, E. Niesters, H.G.M. Cornelissen, J.J. Trenschel, R. Thijsen, S.F. Loon, A.M. van Verdonck, L.F. Frassoni, F. |
2001-01-01
|
